SAILIFE Sai Life Q1 FY26 results (Apr–Jun 2025) and concall
Sai Life Sciences delivered an exceptionally strong start to FY26, characterized by triple-digit growth in its CDMO segment and a significant turnaround in bottom-line profitability. Management is aggressively investing in capacity, with a ₹700 crore capex plan for the current year to double Process R&D and expand manufacturing by 80% by 2027. The company is successfully pivoting toward high-growth modalities like ADCs and oligonucleotides while benefiting from 'China Plus One' diversification trends.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 396 | 440 | 580 | 496 |
| EBITDA | 102 | 120 | 158 | 121 |
| Net profit | 42 | 54 | 88 | 60 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
